Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD11B1 | P28845 | 9/20 | 0.60 |
| ▸ | OPRL1 | P41146 | 4/20 | 0.50 |
| ▸ | OPRM1 | P35372 | 4/20 | 0.50 |
| ▸ | OPRK1 | P41145 | 3/20 | 0.50 |
| ▸ | RXRA | P19793 | 1/20 | 0.48 |
| ▸ | RXRB | P28702 | 1/20 | 0.48 |
| ▸ | RXRG | P48443 | 1/20 | 0.48 |
| ▸ | CCR2 | P41597 | 5/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14280711 | 0.86 | OPRL1 (0.64) | HSD11B1OPRL1OPRM1OPRK1CCR2 | |
| SCHEMBL16801704 | 0.81 | KDM4E (0.65) | HSD11B1OPRL1OPRM1OPRK1CCR2 | |
| SCHEMBL3066058 | 0.81 | HSD11B1 (0.65) | HSD11B1OPRL1OPRM1OPRK1CCR2 | |
| SCHEMBL6158491 | 0.80 | HSD11B1 (0.66) | HSD11B1OPRL1OPRM1OPRK1CCR2 | |
| SCHEMBL2267177 | 0.80 | HSD11B1 (0.63) | HSD11B1OPRL1OPRM1OPRK1 | |
| SCHEMBL21714144 | 0.79 | HSD11B1 (0.52) | HSD11B1OPRL1OPRM1OPRK1CCR2 | |
| SCHEMBL13090626 | 0.77 | HSD11B1 (0.72) | HSD11B1OPRL1OPRM1OPRK1CCR2 | |
| SCHEMBL3062803 | 0.77 | HSD11B1 (0.91) | HSD11B1OPRL1OPRM1OPRK1CCR2 | |
| SCHEMBL27823059 | 0.77 | HSD11B1 (0.58) | HSD11B1OPRL1OPRM1OPRK1 | |
| SCHEMBL4059915 | 0.77 | HSD11B1 (0.62) | HSD11B1OPRL1OPRM1OPRK1CCR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080015214-A1 | 3-PIPERIDIN-4-YL-INDOLE ORL-1 RECEPTOR MODULATORS | JANSSEN PHARMACEUTICA, N.V. (BE) | 2008-01-17 | — | — | US | disclosed |
| US-20080015214-A1 | 3-PIPERIDIN-4-YL-INDOLE ORL-1 RECEPTOR MODULATORS | JANSSEN PHARMACEUTICA, N.V. (BE) | 2008-01-17 | — | — | US | disclosed |
| WO-2007050381-A2 | 3-PIPERIDIN-4-YL-INDOLE ORL-1 RECEPTOR MODULATORS | JANSSEN PHARMACEUTICA, N.V. (BE) | 2007-05-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080015214-A1 | 3-PIPERIDIN-4-YL-INDOLE ORL-1 RECEPTOR MODULATORS | OGFRL1, OPRL1, ORMDL3 | HSD11B1 1538/4885OPRL1 2/4885OPRM1 11/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.